CYP2W1 and adrenal gland cancer: In concordance with the mRNA analysis, in the majority of the non-adrenal normal tissues, CYP2W1 immunoreactivity was absent or low (H-score 0–1 in 72%, 2 in 25% and 3 in 3% of cases), whereas it was significantly higher in our series of non-adrenal cancers (H-score 0–1 in 56%, 2 in 36% and 3 in 8% of cases, P<0.05 vs normal tissues, Figure 2B).